ATE307132T1 - Purin derivate als a2b adenosin rezeptor antagonisten - Google Patents

Purin derivate als a2b adenosin rezeptor antagonisten

Info

Publication number: ATE307132T1
Authority: AT; Austria
Prior art keywords: optionally substituted; receptor antagonists; adenosine receptor; purine derivatives; sup
Prior art date: 2001-06-29

Application number

AT02749704T

Other languages

English (en)

Inventor

Venkata Palle

Vaibhav Varkhedkar

Jeff A Zablocki

Dengming Xiao

Original Assignee

Cv Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-29

Filing date

2002-06-27

Publication date

2005-11-15

2002-06-27 Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc

2005-11-15 Application granted granted Critical

2005-11-15 Publication of ATE307132T1 publication Critical patent/ATE307132T1/de

Links

229940121359 adenosine receptor antagonist Drugs 0.000 title abstract 2
239000000296 purinergic P1 receptor antagonist Substances 0.000 title abstract 2
101150078577 Adora2b gene Proteins 0.000 title 1
229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
150000003212 purines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1
125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AT02749704T 2001-06-29 2002-06-27 Purin derivate als a2b adenosin rezeptor antagonisten ATE307132T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30220801P	2001-06-29	2001-06-29
PCT/US2002/020631 WO2003002566A1 (en)	2001-06-29	2002-06-27	Purine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE307132T1 true ATE307132T1 (de)	2005-11-15

Family

ID=23166757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02749704T ATE307132T1 (de)	2001-06-29	2002-06-27	Purin derivate als a2b adenosin rezeptor antagonisten

Country Status (10)

Country	Link
US (2)	US6770651B2 (de)
EP (1)	EP1401837B1 (de)
JP (1)	JP4335000B2 (de)
KR (2)	KR100897219B1 (de)
AT (1)	ATE307132T1 (de)
CA (1)	CA2451244C (de)
DE (1)	DE60206756T2 (de)
DK (1)	DK1401837T3 (de)
ES (1)	ES2247356T3 (de)
WO (1)	WO2003002566A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRM20010465A1 (it) *	2001-07-31	2003-01-31	Sigma Tau Ind Farmaceuti	Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
ES2279903T3 (es) *	2001-12-18	2007-09-01	Cv Therapeutics, Inc.	Antagonistas del receptor a2a de adenosina.
DE60322748D1 (de) *	2003-05-06	2008-09-18	Cv Therapeutics Inc	Xanthinderivate als a2b-adenosinrezeptorantagonisten
NL1023355C2 (nl) *	2003-05-07	2004-11-09	Oce Tech Bv	Hot melt inkt omvattend een mengsel van kleurstoffen.
TWI372050B (en)	2003-07-03	2012-09-11	Astex Therapeutics Ltd	(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2005009445A1 (en) *	2003-07-22	2005-02-03	Cv Therapeutics, Inc.	A1 adenosine receptor antagonists
WO2005047268A2 (en) *	2003-11-10	2005-05-26	X-Ceptor Therapeutics, Inc.	Substituted pyrimidine compositions and methods of use
WO2005058898A2 (en) *	2003-12-16	2005-06-30	Ranbaxy Laboratories Limited	Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
KR101334511B1 (ko)	2004-12-30	2013-11-29	아스텍스 테라퓨틱스 리미티드	Ｃｄｋ, ｇｓｋ 및 오로라 키나아제의 활성을 조절하는피라졸 화합물
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
JP2009504803A (ja)	2005-08-22	2009-02-05	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｔｌｒアゴニスト
US20070225304A1 (en) *	2005-09-06	2007-09-27	Pharmacopeia Drug Discovery, Inc.	Aminopurine derivatives for treating neurodegenerative diseases
ES2274712B1 (es) *	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
WO2007077435A1 (en)	2005-12-30	2007-07-12	Astex Therapeutics Limited	Pharmaceutical compounds
EP2029597A4 (de) *	2006-05-31	2011-11-23	Univ California	Purinanaloga
EP2049119A2 (de)	2006-06-29	2009-04-22	Astex Therapeutics Limited	Pharmazeutische kombinationen von 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-harnstoff
US7470697B2 (en) *	2006-09-01	2008-12-30	Adenosine Therapeutics, Llc	Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
ES2456964T3 (es)	2007-02-07	2014-04-24	The Regents Of The University Of California	Conjugados de agonistas de TLR sintéticos y usos de los mismos
WO2009052310A1 (en) *	2007-10-16	2009-04-23	Cv Therapeutics, Inc	A3 adenosine receptor antagonists
JP2011511073A (ja) *	2008-02-07	2011-04-07	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｔｌｒ７活性化物質による膀胱の疾患の治療
EP2268641B1 (de)	2008-03-26	2014-09-03	Advinus Therapeutics Pvt. Ltd.	Heterocyclische verbindungen als adenosinrezeptorantagonist
WO2010009194A1 (en) *	2008-07-16	2010-01-21	King Pharmaceuticals Research And Development, Inc.	Methods of treating atherosclerosis
WO2010093436A2 (en) *	2009-02-11	2010-08-19	Carson Dennis A	Toll-like receptor modulators and treatment of diseases
JP5765239B2 (ja)	2009-03-13	2015-08-19	アドヴィナス・セラピューティックス・リミテッド	置換縮合ピリミジン化合物
HUE025704T2 (en) *	2009-03-20	2016-04-28	Sigma Tau Ind Farmaceuti	Oxidized triazolyl purine derivatives used as adenosine A2A receptor ligands and their use as medicaments
US8796290B2 (en)	2009-11-09	2014-08-05	Advinus Therapeutics Limited	Substituted fused pyrimidine compounds, its preparation and uses thereof
BR112012032766A2 (pt)	2010-06-30	2019-09-24	Gilead Sciences Inc	uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
AU2011303420B2 (en)	2010-09-13	2014-03-20	Impetis Biosciences Ltd.	Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
DE102011005232A1 (de)	2011-03-08	2012-09-13	AristoCon GmbH & Co. KG	Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AR085942A1 (es)	2011-04-07	2013-11-06	Gilead Sciences Inc	Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
EP3226861A2 (de) *	2014-12-05	2017-10-11	Centre National de la Recherche Scientifique (CNRS)	Verbindungen zur behandlung von zystischer fibrose
WO2017188287A1 (ja) *	2016-04-26	2017-11-02	大日本住友製薬株式会社	置換プリン誘導体
US11697851B2 (en)	2016-05-24	2023-07-11	The Regents Of The University Of California	Early ovarian cancer detection diagnostic test based on mRNA isoforms
MX2021010701A (es) *	2019-03-05	2022-02-21	F Star Therapeutics Inc	Compuestos, composiciones y metodos para el tratamiento de enfermedad.
WO2024105159A1 (en) *	2022-11-16	2024-05-23	University Of Zurich	Ligands of the m6a-rna readers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4954504A (en) *	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US6545002B1 (en) *	1999-06-01	2003-04-08	University Of Virginia Patent Foundation	Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
AU760071B2 (en)	1999-08-31	2003-05-08	Vanderbilt University	Selective antagonists of A2B adenosine receptors
ITRM20010465A1 (it) *	2001-07-31	2003-01-31	Sigma Tau Ind Farmaceuti	Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
US6897208B2 (en) *	2001-10-26	2005-05-24	Aventis Pharmaceuticals Inc.	Benzimidazoles
ES2279903T3 (es) *	2001-12-18	2007-09-01	Cv Therapeutics, Inc.	Antagonistas del receptor a2a de adenosina.

2002
- 2002-06-27 JP JP2003508947A patent/JP4335000B2/ja not_active Expired - Lifetime
- 2002-06-27 ES ES02749704T patent/ES2247356T3/es not_active Expired - Lifetime
- 2002-06-27 KR KR1020087020714A patent/KR100897219B1/ko not_active Expired - Lifetime
- 2002-06-27 DK DK02749704T patent/DK1401837T3/da active
- 2002-06-27 EP EP02749704A patent/EP1401837B1/de not_active Expired - Lifetime
- 2002-06-27 US US10/184,494 patent/US6770651B2/en not_active Expired - Fee Related
- 2002-06-27 KR KR1020037017083A patent/KR100883292B1/ko not_active Expired - Lifetime
- 2002-06-27 CA CA2451244A patent/CA2451244C/en not_active Expired - Lifetime
- 2002-06-27 WO PCT/US2002/020631 patent/WO2003002566A1/en not_active Ceased
- 2002-06-27 DE DE60206756T patent/DE60206756T2/de not_active Expired - Lifetime
- 2002-06-27 AT AT02749704T patent/ATE307132T1/de active
2004
- 2004-04-30 US US10/837,290 patent/US7238700B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2451244A1 (en)	2003-01-09
KR20040023634A (ko)	2004-03-18
EP1401837B1 (de)	2005-10-19
HK1064096A1 (en)	2005-01-21
US7238700B2 (en)	2007-07-03
DE60206756T2 (de)	2006-07-13
US20030064999A1 (en)	2003-04-03
KR100883292B1 (ko)	2009-02-11
DK1401837T3 (da)	2005-11-07
EP1401837A1 (de)	2004-03-31
WO2003002566A1 (en)	2003-01-09
JP2004536102A (ja)	2004-12-02
US6770651B2 (en)	2004-08-03
ES2247356T3 (es)	2006-03-01
KR20080081208A (ko)	2008-09-08
JP4335000B2 (ja)	2009-09-30
US20040209899A1 (en)	2004-10-21
KR100897219B1 (ko)	2009-05-14
DE60206756D1 (de)	2006-03-02
CA2451244C (en)	2012-01-17

Legal Events

Date

Code

Title

Description

2006-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1401837

Country of ref document: EP

Publication	Publication Date	Title
DE60206756D1 (de)	2006-03-02	Purin derivate als a2b adenosin rezeptor antagonisten
TR200201001T2 (tr)	2002-09-23	Pürin türevleri
ATE302205T1 (de)	2005-09-15	Thieno- und furopyrimidin derivate als a2a- rezeptor antagonisten
CY1117132T1 (el)	2017-04-05	Παραγωγο θειαζολιου
TR200200161T2 (tr)	2002-05-21	Benzimidazol türevleri ve onların fosfodiesteraz olarak kullanımı.
WO2003022216A3 (en)	2003-12-11	Biaryl substituted purine derivatives as potent antiproliferative agents
MXPA04003795A (es)	2004-07-30	Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos.
DE60236719D1 (de)	2010-07-29	Purinderivate als antagonisten an purinergen rezeptoren
ATE424207T1 (de)	2009-03-15	Triazoloä4,5-düpyrimidinderivate und ihre verwendung als antagonisten purinerger rezeptoren
PT1140851E (pt)	2004-12-31	4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
PE20010430A1 (es)	2001-04-14	DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
TNSN07154A1 (en)	2008-11-21	Purine derivatives for use as adenosin a-2a receptor agonists
ATE254132T1 (de)	2003-11-15	Antivirale pyrimidin nucleoside derivate
WO2003022805A3 (en)	2004-01-22	Heterocycle substituted purines as antiproliferative agents
LV12712A (lv)	2001-09-20	Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method
BR0008770A (pt)	2002-01-08	Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
AR037680A1 (es)	2004-12-01	Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d
ATE266021T1 (de)	2004-05-15	Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren
ES2150903T3 (es)	2000-12-16	Derivados de 2-aralcoxi y 2-alcoxi adenosina de utilidad como vasodilatadores coronarios y como agentes antihipertensivos.
TR200401622T4 (tr)	2004-08-23	Pürin türevleri
WO2003022219A3 (en)	2003-11-13	Biarylamino purine antiproliferative agents
ATE407935T1 (de)	2008-09-15	Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren
ATE418555T1 (de)	2009-01-15	A2a-adenosinrezeptorantagonisten
CY1105879T1 (el)	2011-02-02	Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα
WO2003068776A1 (en)	2003-08-21	[1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES